Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib in Treatment-Naïve EGFR-Mutant Advanced NSCLC
NCT00411047Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2005
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Massachusetts General Hospital. Started Sep 2005; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00411047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00411047.